Dr Reddys Laboratories Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg

NSE: DRREDDY Large Cap ISIN: INE089A01031
As on 23 December 2024 at 04:11 IST
As on 23 December 2024 at 04:11 IST
1,325.60
+ 50.20
(3.94%)
Over 1 Month
12.41%
Over 6 Months
12.52%
Over 1 Year
20.42%
Over 3 Years
47.31%

Dr Reddys Laboratories Ltd Summary

Close 1,325.60
Open 1,275
High 1,331.35
Low 1,271.65
Volume 71,85,903
Net Turnover (in ₹) 10,14,38,28,011.70
52 Week High 1,421.49
52 Week Low 1,094.24
52Wk High / Low
1,094.24
1,421.49

Dr Reddys Laboratories Ltd Key Financial Data

Market Cap (in ₹ Cr) 1,12,115.62
EPS (TTM) 57.64
Book Value (BV) 322.48
Div. Yield 0.60
P/E (TTM) 23.29
Price/Book Value 4.16
Delivery % 49.99
Face Value 1

Dr Reddys Laboratories Ltd Key Ratios

P/E ratio 23.65
P/B ratio 4.22
EV to Sales 5.25
PEG Ratio 0.36
ROA 17.27
ROE 19.42
Debt-Equity 0.02
Net Profit Margin 22.29
Operating Profit Margin 34.84

Dr Reddys Laboratories Ltd Peer Comparison

Company LTP Market Cap (in ₹ Cr)
Dr Reddys Laboratories Ltd ₹1,342.45 ₹1,12,015.49
Sun Pharmaceuticals Industries Ltd ₹1,808.50 ₹4,33,919.73
Divis Laboratories Ltd ₹5,844.75 ₹1,55,159.75
Cipla Ltd ₹1,472.45 ₹1,18,917.13
Torrent Pharmaceuticals Ltd ₹3,434.25 ₹1,16,225.41
Mankind Pharma Ltd ₹2,803.45 ₹1,12,323.63

Dr Reddys Laboratories Ltd News

Dr Reddys Laboratories Ltd gains for third straight session

Dr Reddys Laboratories Ltd is quoting at Rs 1356.8, up 2.35% on the day as on 12:49 IST on the NSE. The stock is up 22.14% in last one year as compared to a 11.83% jump in NIFTY and a 39.64% jump in the Nifty Pharma index.

20 Dec 2024

Dr Reddys Laboratories allots 13,080 equity shares under ESOS

20 Dec 2024

Dr Reddy's Labs launches immuno-oncology drug Toripalimab in India

Dr Reddy's Laboratories has announced the launch of Toripalimab in India, a new biological entity (NBE) that is used for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).

28 Nov 2024

Dr Reddys launches immuno-oncology drug - Toripalimab in India

28 Nov 2024

DRL slips after Hyderabad facility gets 7 observations from USFDA

Dr Reddy's Laboratories (DRL) declined 1.07% to Rs 1200.95 after the US Food and Drug Administration (USFDA) concluded its Good manufacturing practice (GMP) inspection with seven observations at API manufacturing facility in Bollaram, Hyderabad.

21 Nov 2024

Dr Reddys Laboratories Ltd Financials

Profit and Loss

Particulars (in ₹ Cr.) FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Total Revenue20,346.1017,553.8014,887.2014,150.2012,593.60
Total Expenses14,554.8013,687.8012,663.4011,0949,817.80
Profit Before Tax5,791.303,8662,223.803,056.202,775.80
Profit After Tax4,3422,612.801,623.202,186.402,937.70
Operating Profit after Depreciation5,813.103,882.902,261.803,102.902,823.60

Balance Sheet

Particulars (in ₹ Cr.) FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Fixed Assets7,628.207,220.606,164.405,8684,461.60
Total Non Current Assets12,543.4011,586.5011,004.3010,685.409,369.10
Total Current Assets17,815.9013,788.3013,491.3010,944.2010,106.70
TOTAL ASSETS30,359.3025,374.8024,495.6021,629.6019,475.80
Total Shareholder's Fund24,240.8020,474.2018,336.2016,983.7015,191.90

Cash Flow

Particulars (in ₹ Cr.) FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Net Cash from Operating Activities3,449.705,052.901,338.703,514.201,839.20
Net Cash used in Investing Activities-3,428.70-3,403.20-1,990.10-1,453.60-1,689.20
Net Cash used in Financing Activities68.10-2,696.90505.50-794.30-224.10

Dr Reddys Laboratories Ltd Corporate Actions

Dr Reddys Laboratories Ltd

₹40/Share

Announcement Date 16 Jul 2024
Record Date 17 Jul 2024
Div Yield 800%

About Dr Reddys Laboratories Ltd

Dr. Reddy’s Laboratories Ltd is a global pharmaceutical company that aims to make medicines more approachable. Founded in 1984 by Dr. Kallam Anji Reddy, the company has grown significantly over the last 40 years. Headquartered in Hyderabad, Telangana, India, Dr. Reddy’s operates worldwide. They develop, manufacture, and sell a variety of pharmaceutical products. These include active pharmaceutical ingredients (APIs), generics, biosimilars, and over-the-counter (OTC) products.

Dr. Reddy’s is known for producing medicines that target a range of therapeutic areas. Their medicines can treat issues related to cardiovascular health, diabetes, oncology, and dermatology. Among its most recognised products is Omes (omeprazole). It is a medication for gastrointestinal issues.

Although Dr. Reddy’s is not the largest pharmaceutical company, it is highly regarded for its innovative approach. The company continues to grow its influence within the industry by focusing on quality and affordability.
The promoters hold approximately 26.65 % of the company’s shares. This reflects its strong commitment to its growth and future direction. Here is a list of its top managing promoters - ‘
  • K Satish Reddy
  • G V Prasad
  • Claudio Albrecht

The company’s registered office is located at Banjara Hills in Hyderabad, Telangana. Its registrars and transfer agents are situated in Hyderabad as well. Dr. Reddy’s has built a solid reputation for its mission of providing access to affordable and innovative medicines. The company’s vision and mission reflect this focus and guide everything it does.

The objective of Dr. Reddy’s Laboratories Ltd

Dr. Reddy’s Laboratories has a clear vision and mission that guides its actions and decisions. These principles show its commitment to improving global health by enabling access to good medicines.

The vision of Dr. Reddy’s is to become a leading global pharmaceutical company. Their aim is to provide affordable and innovative medicines for healthier lives. This vision highlights the company’s dedication to addressing unmet medical needs and improving the quality of life for patients all over the world. Dr. Reddy’s does not just focus on expanding its business but aims to make a real impact by ensuring that advanced healthcare solutions reach those who need them most.
Dr. Reddy’s wants to bridge the gap between high-quality healthcare solutions and the people who require them. The company strives to meet this vision by offering medicines that are effective, accessible, and affordable.

The company’s mission is clear: to give access to affordable and effective medicines because "good health can’t wait." This simple yet powerful mission statement shows that Dr. Reddy’s knows how crucial it is for patients to get access to good medications. The company places a strong emphasis on improving health outcomes. It is this mission that drives every part of its business—from research and development to marketing and sales.

Innovation lies at the heart of Dr. Reddy’s Laboratories. The company invests heavily in research and development (R&D) to discover new therapies and improve existing ones. It uses cutting-edge technology to stay ahead of the latest scientific advancements. Dr. Reddy’s creates medicines that not only work but are also more accessible to a wider audience.

Making healthcare affordable is a core aspect of Dr. Reddy’s mission. The company is committed to making high-quality medicines available at prices that people can afford. One way Dr. Reddy’s does this is by offering a broad portfolio of generic medicines. These medicines provide cost-effective alternatives to expensive brand-name drugs.

Generics play a crucial role in healthcare systems worldwide by reducing the financial burden on patients. They do this while maintaining the same level of efficacy as their branded counterparts. Through these lower-cost alternatives, Dr. Reddy’s helps make high-quality healthcare more accessible for millions of people across the globe.

Dr. Reddy’s Laboratories is not just focused on India but operates globally. It makes its presence felt in key markets like the United States, Europe and emerging markets across Africa and Latin America. This global reach allows the company to provide much-needed medicines to patients all over the world.

One of the ways Dr. Reddy’s ensures its products are available globally is through partnerships with other organisations. These partnerships help the company tap into new markets and ensure that its medicines are available to people from all walks of life.
At the heart of Dr. Reddy’s strategy is a focus on the patient. The company places a strong emphasis on understanding and addressing the needs of its customers. Whether that means improving product quality, speeding up time to market, or providing better service. This patient-centric approach ensures that Dr. Reddy’s delivers solutions that make a difference in the patient’s lives.

Dr. Reddy’s Laboratories Ltd is much more than just a pharmaceutical company. It is a pioneer in making healthcare affordable and accessible to millions of people across the globe. Through its clear vision and mission, the company is driving positive change in the world of healthcare by focusing on innovation, affordability, and sustainability. Through its unwavering focus on making "good health accessible", Dr. Reddy’s Laboratories is truly living up to its mission every day.

Dr Reddys Laboratories Ltd Stock Analysis

  1. Annual revenue for Dr Reddys Laboratories Ltd increased by 15.91% to ₹20,346.10 crore in FY 2024 from ₹17,553.80 crore in FY 2023.
  2. Annual Net Profit for Dr Reddys Laboratories Ltd increased by 66.18% to ₹4,342 crore in FY 2024 from ₹2,612.80 crore in FY 2023.
  3. Promoter Shareholding in Dr Reddys Laboratories Ltd decreased by 0.03% in the most recent quarter, from 26.65% in June 2024 to 26.64% in September 2024.
  4. Dr Reddys Laboratories Ltd delivered a 1-year return of 20.42% compared to the Nifty 50, which provided a return of 11.52% as of the last trading session.
  5. Dr Reddys Laboratories Ltd share price moved remains unchanged by 0.00% from its previous close of INR ₹1,325.60. The latest Dr Reddys Laboratories Ltd share price is INR ₹1,325.60.
  6. Dr Reddys Laboratories Ltd share price today has been at a low of 1,317.40 and a high of 1,368.70. Over the past 52 weeks, the Dr Reddys Laboratories Ltd share price has seen a low of 1,094.24 and a high of 1,421.49.

FAQ’s

What is the share price of Dr Reddys Laboratories Ltd today?

Dr Reddys Laboratories Ltd share price as on 22 Dec 2024 is ₹ 1325.6

What is the Market Cap of Dr Reddys Laboratories Ltd?

The market cap of Dr Reddys Laboratories Ltd stock is ₹1,12,115.62 Cr.

What is the PE Ratio of Dr Reddys Laboratories Ltd?

The Price to Earnings (P/E) Ratio of Dr Reddys Laboratories Ltd is 23.65

What is the PB Ratio of Dr Reddys Laboratories Ltd?

The Price to Book (P/B) Ratio of Dr Reddys Laboratories Ltd is 4.22

What is the 52 week high of Dr Reddys Laboratories Ltd Share Price?

The 52 week high of Dr Reddys Laboratories Ltd share price stands at ₹1,421.49

What is the 52 week low of Dr Reddys Laboratories Ltd Share Price?

The 52 week low of Dr Reddys Laboratories Ltd share price stands at ₹1,094.24

Get started with us today and
start building your wealth journey